Search Results

Press Releases

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions

May 27, 2026

·

12 min read

Press Releases

Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access

February 24, 2026

·

15 min read

Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.

Business

Novo Nordisk to present new data from key diabetes and obesity trials at the 60th Annual Meeting of the European Association for the Study of Diabetes

September 6, 2024

·

5 min read

Business

California and Illinois tennis players named recipients of 2019 Novo Nordisk Donnelly Award Scholarships

Scholarships support young tennis players with Diabetes; eight regional recipients also named

May 21, 2019

·

4 min read

Pharm Country

Novo Nordisk issues voluntary nationwide recall of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy® product samples due to improper storage temperature conditions

Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level.

May 7, 2021

·

4 min read

Policy

Novo Nordisk A/S To Pay $58.7 Million For Failing To Warn Doctors Of Cancer Risk For Diabetes Drugs

September 6, 2017

·

2 min read

Pharm Country

Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com

- COVID-19 Patient Assistance Program: Eligible patients can continue to enroll in our Diabetes Patient Assistance Program and receive a free 90-day supply of insulin until June 30, 2021 - My$99Insulin Program: Patients who enrolled in the cash card program in 2020 must reregister to determine if they are eligible to continue participating in 2021

January 4, 2021

·

4 min read

BioCapital

ACC, Novo Nordisk Partner to Improve Cardiovascular Disease Management in Patients with Type 2 Diabetes

The American College of Cardiology, in partnership with Novo Nordisk Inc., is launching Transforming Cardiovascular Risk in Diabetes (TRANSFORM CVRiD), a new, two-year health care quality initiative to promote cardiovascular risk reduction and care for people with Type 2 diabetes.

September 10, 2020

·

4 min read

Pharm Country

Novo Nordisk to present research across diabetes and obesity portfolio at the 81st Annual American Diabetes Association Scientific Sessions

Novo Nordisk announced that new data from more than 30 abstracts will be presented from the company’s approved and investigational medicines highlighting its broad diabetes and obesity portfolio at the upcoming 81st Annual Scientific Sessions of the American Diabetes Association.

June 16, 2021

·

6 min read